Vical Inc (VICL): Lawrence Russell Smith , VP, Vaccine Research of Vical Inc sold 54 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $4.46 per share for a total value of $240.84 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 14, 2016, Robert C Merton (director) purchased 9,000 shares at $4.35 per share price.On Jun 10, 2016, Vijay B Samant (CEO) purchased 15,700 shares at $4.72 per share price.Also, On Jun 8, 2016, R Gordon Douglas (director) purchased 10,078 shares at $4.41 per share price.On Jun 6, 2016, Gary A Lyons (director) purchased 7,078 shares at $4.39 per share price.
Vical Incorporated: On Monday, Jul 11, 2016 heightened volatility was witnessed in Vical Incorporated which led to swings in the share price. The shares opened for trading at $4.46 and hit $4.55 on the upside , eventually ending the session at $4.51, with a gain of 0.45% or 0.02 points. The heightened volatility saw the trading volume jump to 8,905 shares. The 52-week high of the share price is $7.2 and the company has a market cap of $42 M . The 52-week low of the share price is at $2.808.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent or partnered development programs in the areas of infectious disease consisted of: Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2) a cause of recurrent genital herpes and a completed preclinical program with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.